相关实验视频

Updated: Jun 1, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

在前性和随机的早期杀菌活性研究中,孔特佐利德在结核病治疗中具有与线索利德相当的疗效

Guanglu Jiang¹, Rongmei Liu², Yi Xue¹

¹National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.

Infection and drug resistance

|January 20, 2025

概括

康特佐利德 (CZD) 在结核病治疗中表现出与林佐利德 (LZD) 相似的疗效,安全性更高. 虽然CZD的初始作用较慢,但它的有效性随着时间的推移而增加,为LZD提供了潜在的替代方案.

科学领域:

传染性疾病传染性疾病
药理学药理学是指药理学的学科.
微生物学微生物学

背景情况:

康特佐利德 (CZD) 是一种新型的Linezolid (LZD) 类比,具有抗结核病 (TB) 的强效活性.
与LZD相比,CZD具有潜在的更安全的副作用.
这项研究旨在评估结核病患者中CZD与LZD的早期杀菌活性 (EBA).

研究的目的:

为了在肺结核患者中比较康特佐利德 (CZD) 与林佐利德 (LZD) 的早期杀菌活性 (EBA).
评估液体培养中的时间到阳性 (TTP) 作为细菌减少的衡量标准.
评估CZD作为结核病治疗中LZD的潜在替代方案.

主要方法:

一项为期14天的单疗法研究,涉及天真,涂抹阳性肺结核病患者.
随机分配给600毫克LZD每天一次或800毫克CZD每天两次.
每天收集唾液样本以清算酸性快速菌根 (AFB) 和MGIT960液体培养TTP分析.

主要成果:

在CZD和LZD组中,EBA0-14的值分别为0.08±0.12和0.03±0.10 log CFU/mL/day.
在CZD中,TTP0-14增加了38.6 ± 43.69小时,在LZD中增加了27.7 ± 78.21小时.
经过几天的治疗,LZD表现出快速的初始细菌减少,而CZD表现出更高的疗效.

结论:

在这项针对肺结核的早期细菌杀菌活性研究中,800 mg两日两次的孔特佐利德的疗效与600 mgQD的林尼佐利德的疗效相当.
康泰索利德的初始杀菌效果较慢,但在几天后超过了Linezolid的疗效.
CZD的类似疗效和改善的安全性概况表明它是结核病治疗的可行替代方案.

关键词:

康特佐利德的使用情况早期的细菌杀菌活性.在线zolidlid是什么意思时间到积极性的时间.

更多相关视频

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...